Comparison
22q11 2 Deletion Syndrome Cn294181 vs 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Clinical comparison between 22q11 2 Deletion Syndrome CN294181 and 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 for differential diagnosis and treatment planning.
22q11 2 Deletion Syndrome Cn294181
A genetic condition where a small piece of chromosome 22 is missing. It can affect the heart, immune system, and development. Treatment involves managing symptoms across multiple specialties.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
6 comparison axes
Onset
22q11 2 Deletion Syndrome Cn294181
0-null
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
Onset patterns differ
Severity
22q11 2 Deletion Syndrome Cn294181
severe
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
Different severity levels
Chronic
22q11 2 Deletion Syndrome Cn294181
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
Differing course
Communicable
22q11 2 Deletion Syndrome Cn294181
No
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
Different transmission
Body System
22q11 2 Deletion Syndrome Cn294181
congenital
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Same/different system
Category
22q11 2 Deletion Syndrome Cn294181
genetic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Different category
Bottom line
22q11-2-deletion-syndrome-CN294181 and 17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 22q11 2 Deletion Syndrome Cn294181 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Discriminating power |
|---|---|---|---|
| Congenital anomalies | May include cardiac, palatal, facial, or developmental anomalies; features vary widely. | Genital development may be atypical; major nonendocrine congenital anomalies are not the defining pattern. | High |
| Blood pressure | Hypertension is not a core feature, although associated conditions may occur. | Hypertension and hypokalemia may occur from mineralocorticoid excess. | High |
| Puberty | Pubertal development is not the primary defining problem. | Absent or incomplete puberty and sex-steroid deficiency are characteristic. | Moderate |
When to favor each condition
Choose 22q11 2 Deletion Syndrome Cn294181 when
Congenital heart, palate, immune, or developmental concerns
This multisystem pattern supports chromosomal microarray or targeted 22q11.2 testing.
High
Hypocalcemia with congenital features
Parathyroid dysfunction can occur in 22q11.2 deletion and warrants evaluation.
Moderate
Family or prenatal suspicion of microdeletion
Genetic confirmation distinguishes it from an endocrine enzyme defect.
High
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with atypical genital development
This combination suggests disordered adrenal and gonadal steroid synthesis.
High
Absent puberty with low sex steroids
Enzyme deficiency can impair cortisol and sex-steroid production.
Moderate
Steroid profile suggests CYP17A1-related block
Specialist endocrine and genetic testing can confirm the diagnosis.
High
How key tests differ
| Test | 22q11 2 Deletion Syndrome Cn294181 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Interpretation |
|---|---|---|---|
| Genetic test | Deletion involving 22q11.2 may be detected. | Pathogenic CYP17A1 variants may be found. | Different genetic targets; a negative result does not exclude all related disorders. |
| Steroid profile | No specific steroid-synthesis pattern is expected. | Pattern may suggest impaired 17-hydroxylase/17,20-lyase activity. | Interpret only with age, sex, and clinical context; no cutoff is supplied here. |
| Immune and calcium studies | Low calcium or immune abnormalities may be present. | These are not the primary expected abnormalities. | Abnormal results support further evaluation but are not independently diagnostic. |
Prognosis comparison
22q11 2 Deletion Syndrome Cn294181
- Outcome
- Chronic and highly variable; many complications are manageable, but outcome depends on affected organs.
- Factors
- Cardiac, immune, calcium, and developmental involvement.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine disorder; long-term outcome depends on hormone balance and blood-pressure control.
- Factors
- Severity of enzyme deficiency, puberty, electrolytes, and treatment adherence.
Time frame: Lifelong for both; exact prognosis is not established from the supplied data.
Early recognition, specialist follow-up, and individualized management.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiovascular effects | Congenital heart disease may be present and clinically important. Hypertension and electrolyte imbalance may cause cardiovascular risk. Mechanisms differ; management is specialist-directed. |
| Endocrine effects | Hypocalcemia from parathyroid dysfunction may occur. Cortisol and sex-steroid deficiency may require lifelong replacement. Do not infer doses or exact laboratory thresholds from this comparison. |
| Development and fertility | Learning, speech, or developmental differences may occur. Pubertal delay and impaired fertility may occur. Severity and outcomes vary and are not established uniformly. |
Patient education highlights
- HighDifferent causes
One is a chromosome 22 microdeletion; the other is a steroid-enzyme disorder. They are not interchangeable diagnoses.
- HighSpecialist care
Care may involve genetics, endocrinology, cardiology, immunology, or developmental services as indicated.
- MediumTest results
An abnormal laboratory result is not itself a diagnosis and should be interpreted by a clinician.